395 related articles for article (PubMed ID: 9661897)
1. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
3. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
8. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
9. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
10. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
15. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer.
Wang CX; Koay DC; Edwards A; Lu Z; Mor G; Ocal IT; Digiovanna MP
Breast Cancer Res Treat; 2005 Aug; 92(3):251-63. PubMed ID: 16155796
[TBL] [Abstract][Full Text] [Related]
17. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
20. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
